Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cell Exosomes for Non-arteritic Ischemic Optic Neuropathy
NCT05147701Phase 1Recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Feb 2022
- Primary completion
- Jan 2028
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cell exosomes in non-arteritic anterior ischemic optic neuropathy (NAION), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 48 months. Started Feb 2022; status: recruiting.
02
Drugs
mesenchymal stem cell exosomes
03
Conditions
non-arteritic anterior ischemic optic neuropathy (NAION)
Beyond the preview
Go deeper on NCT05147701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147701.